CA Stock MarketDetailed Quotes

GWS Xtacy Therapeutics Corp

Watchlist
  • 0.045
  • 0.0000.00%
15min DelayMarket Closed Sep 25 16:00 ET
2.21MMarket Cap-2.25P/E (TTM)

Xtacy Therapeutics Corp Key Stats

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Jun 30, 2023
(Q2)Mar 31, 2023
(Q1)Dec 31, 2022
(FY)Sep 30, 2022
(Q4)Sep 30, 2022
(Q3)Jun 30, 2022
(Q2)Mar 31, 2022
(Q1)Dec 31, 2021
(FY)Sep 30, 2021
(Q4)Sep 30, 2021
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
140.6K
55.53%-40.6K
260.99%36K
-333.02%-426.3K
-4,837.37%-312.63K
0
-37,671.60%-91.3K
-719.42%-22.36K
-60.19%-98.45K
40.29%-6.33K
Net income from continuing operations
---362.52K
-146.29%-259.13K
62.79%-157.6K
61.81%-1.37M
65.94%-839.98K
--0
69.36%-105.21K
-158.64%-423.54K
-160.65%-3.58M
-107.45%-2.47M
Operating gains losses
----
----
----
96.18%-11.43K
----
----
----
--100K
-978.25%-298.74K
----
Remuneration paid in stock
--0
----
----
--0
--0
--0
----
----
848.10%3.03M
835.67%2.54M
Other non cashItems
--828.43K
----
----
18.16%300.87K
38.34%-90.1K
--0
-77.78%50.21K
183.96%340.75K
319.90%254.63K
-142.42%-146.12K
Change In working capital
---325.31K
-78.76%13.53K
589.19%193.6K
30.50%652.99K
74.08%628.87K
--0
-8.19%63.7K
-196.47%-39.58K
485.06%500.4K
204.24%361.26K
-Change in prepaid assets
----
----
----
---297.83K
----
----
----
----
--0
----
-Change in payables and accrued expense
----
----
----
90.01%950.82K
----
----
----
-196.47%-39.58K
376.57%500.4K
--361.26K
Cash from discontinued investing activities
Operating cash flow
--140.6K
55.53%-40.6K
260.99%36K
-333.02%-426.3K
-4,837.37%-312.63K
--0
-37,671.60%-91.3K
-719.42%-22.36K
-60.19%-98.45K
40.29%-6.33K
Investing cash flow
Cash flow from continuing investing activities
Cash from discontinued investing activities
Financing cash flow
Cash flow from continuing financing activities
-140.6K
424.75%40.6K
-132.01%-36K
233.68%400.67K
300.72K
0
-116.66%-12.5K
112.45K
120.08K
0
Net issuance payments of debt
----
----
----
-109.04%-6.78K
----
----
----
----
--75.03K
--0
Net common stock issuance
----
----
----
--407.45K
----
----
----
----
--0
----
Net other financing activities
----
----
-132.01%-36K
----
----
--0
---12.5K
--112.45K
--45.05K
--0
Cash from discontinued financing activities
Financing cash flow
---140.6K
424.75%40.6K
-132.01%-36K
233.68%400.67K
--300.72K
--0
-116.66%-12.5K
--112.45K
--120.08K
--0
Net cash flow
Beginning cash position
--0
--0
--0
540.86%25.63K
-62.71%11.92K
-84.43%11.92K
9,011.65%115.72K
540.86%25.63K
-78.12%4K
2,698.60%31.96K
Current changes in cash
----
----
----
-218.49%-25.63K
-88.20%-11.92K
--0
-237.91%-103.8K
3,401.21%90.09K
251.45%21.63K
-321.63%-6.33K
End cash Position
--0
--0
--0
--0
--0
-62.71%11.92K
-84.43%11.92K
9,011.65%115.72K
540.86%25.63K
540.86%25.63K
Free cash from
--140.6K
55.53%-40.6K
260.99%36K
-333.02%-426.3K
-4,837.37%-312.63K
--0
-37,671.60%-91.3K
-719.42%-22.36K
-60.19%-98.45K
40.29%-6.33K
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion with Explanatory Notes
--
--
--
--
Unqualified Opinion with Explanatory Notes
--
(Q3)Jun 30, 2023(Q2)Mar 31, 2023(Q1)Dec 31, 2022(FY)Sep 30, 2022(Q4)Sep 30, 2022(Q3)Jun 30, 2022(Q2)Mar 31, 2022(Q1)Dec 31, 2021(FY)Sep 30, 2021(Q4)Sep 30, 2021
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 140.6K55.53%-40.6K260.99%36K-333.02%-426.3K-4,837.37%-312.63K0-37,671.60%-91.3K-719.42%-22.36K-60.19%-98.45K40.29%-6.33K
Net income from continuing operations ---362.52K-146.29%-259.13K62.79%-157.6K61.81%-1.37M65.94%-839.98K--069.36%-105.21K-158.64%-423.54K-160.65%-3.58M-107.45%-2.47M
Operating gains losses ------------96.18%-11.43K--------------100K-978.25%-298.74K----
Remuneration paid in stock --0----------0--0--0--------848.10%3.03M835.67%2.54M
Other non cashItems --828.43K--------18.16%300.87K38.34%-90.1K--0-77.78%50.21K183.96%340.75K319.90%254.63K-142.42%-146.12K
Change In working capital ---325.31K-78.76%13.53K589.19%193.6K30.50%652.99K74.08%628.87K--0-8.19%63.7K-196.47%-39.58K485.06%500.4K204.24%361.26K
-Change in prepaid assets ---------------297.83K------------------0----
-Change in payables and accrued expense ------------90.01%950.82K-------------196.47%-39.58K376.57%500.4K--361.26K
Cash from discontinued investing activities
Operating cash flow --140.6K55.53%-40.6K260.99%36K-333.02%-426.3K-4,837.37%-312.63K--0-37,671.60%-91.3K-719.42%-22.36K-60.19%-98.45K40.29%-6.33K
Investing cash flow
Cash flow from continuing investing activities
Cash from discontinued investing activities
Financing cash flow
Cash flow from continuing financing activities -140.6K424.75%40.6K-132.01%-36K233.68%400.67K300.72K0-116.66%-12.5K112.45K120.08K0
Net issuance payments of debt -------------109.04%-6.78K------------------75.03K--0
Net common stock issuance --------------407.45K------------------0----
Net other financing activities ---------132.01%-36K----------0---12.5K--112.45K--45.05K--0
Cash from discontinued financing activities
Financing cash flow ---140.6K424.75%40.6K-132.01%-36K233.68%400.67K--300.72K--0-116.66%-12.5K--112.45K--120.08K--0
Net cash flow
Beginning cash position --0--0--0540.86%25.63K-62.71%11.92K-84.43%11.92K9,011.65%115.72K540.86%25.63K-78.12%4K2,698.60%31.96K
Current changes in cash -------------218.49%-25.63K-88.20%-11.92K--0-237.91%-103.8K3,401.21%90.09K251.45%21.63K-321.63%-6.33K
End cash Position --0--0--0--0--0-62.71%11.92K-84.43%11.92K9,011.65%115.72K540.86%25.63K540.86%25.63K
Free cash from --140.6K55.53%-40.6K260.99%36K-333.02%-426.3K-4,837.37%-312.63K--0-37,671.60%-91.3K-719.42%-22.36K-60.19%-98.45K40.29%-6.33K
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion with Explanatory Notes--------Unqualified Opinion with Explanatory Notes--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.